Cell Counting Market

Market Overview

The global cell counting market size valued at USD 9765.2 million in 2019 and is expected to grow at a 6.5% CAGR during the forecast period.Cell counting is a technique where cells in a culture suspension are enumerated for research and scientific purposes as well as medical reasons. Cell counting helps in maintaining cell cultures and preparing cells for biological procedures and downstream experiments. Cell counting is often done via high-end devices based on various quantification principles such as flow cytometers, spectrometers, cell counters, microplates, and others. Cell counting has applications in pharmaceutical companies, research institutions, diagnostic laboratories, and hospitals.

Market Dynamics

Growing Cell-Based Researches Drive the Market Growth

The increasing number of cellular researches is expected to drive the global cell counting market growth during the forecast period. The global cell counting market growth is primarily driven by factors, such as increased funding for cell-based research to address the rising incidence of chronic diseases such as cancer. According to the World Health Organization (WHO), cancer has been recognized as the second most frequent cause of death across the world with an estimated 9.6 million deaths in 2018. Further, the WHO estimated that about 1 in 6 deaths across the world can be attributed to cancer altogether.

Owing to major advancements in cell-based research, such as stem cells, and cell therapies have found potential therapeutic strategies for cancer treatment. This leads to increased research activities on diseases, such as cancer, leukemia, HIV, and Alzheimer’s, and these researches often require cell counting methods. Thus, the growing researches involving cell counting methods are anticipated to drive the market growth during the forecast period.

Growing Biotechnology and Biopharmaceutical Industries Boost the Market

There has been a surge in the number of biotechnology, biopharmaceutical industries across the globe. Many pharmaceutical companies, such as Pfizer, Novartis, Elli Lilly, and others have channelized significant resources in cellular fermentation for the production of products both in the R&D and production phases. During these processes, cell counting is a vital factor of batch manufacturing, downstream processing, and others. Several R&D level projects are conducted simultaneously boosting the demand for cell counting at every end-user.

The development of enhanced solutions and availability of high-throughput flow cytometry and automated instruments have further made the market products more reliable and have boosted the adoption. Further, the market is also expected to witness exponential growth as blood cell counting has been recognized as vital for the assessment of various diseases. Thus, the growing number of biotechnology and biopharmaceutical industries and advancements in the available instruments are anticipated to boost the market growth during the forecast period.

Regional Analysis

Americas Expected to Account for Fastest Revenue Generating Market

The American market is anticipated to account for the largest revenue-generating market share during the forecast period. The high regional market share can be contributed to increasing focus on biomedical, stem cells, and cancer research along with constant support from the government. Further, the region is burdened with the rising prevalence of chronic diseases, such as cancer and blood diseases, where diagnostics requires the usage of cell counting methods.

According to the American Cancer Society in 2017, 1.68 million new cases of cancer were reported in the U.S., and about 600,920 cancer-caused deaths. This massive upsurge in prevalence has boosted focus on cancer and stem cell research to device therapeutic approaches. Further, the regional market is packed with the presence of market leaders such as Thermo Fischer, Agilent, and others based out of the U.S.

The Asia-Pacific to Record Highest Market Growth

The APAC region is expected to grow at the highest CAGR during the forecast period. The growth can be attributed to the growing number of proteomics, genomics, and stem cell research activities, increasing research funding, increasing investments by pharmaceutical and biotechnology companies in these techniques.

Asia-Pacific is expected to attain a major market share during the forecast period owing to the local presence of certain clinical research and biopharmaceutical companies across this region coupled with the presence of most of the market players in the regional market who constantly seek deeper market penetration. Additionally, the availability of skilled personnel, low development costs, vast genome pool, and less complex regulations for drug development are some of the major factors that attract many pharma companies into the region. These companies often extensively employ these market products in their product development and research.

Segmental Analysis

Clinical and Diagnostic Applications Segment to Record Fastest Growth

Based on application, the clinical and diagnostic application segment is expected to record the fastest growth during the forecast period. This exponential growth of the segment can be attributed to the widespread and increasing applications of cell counting in clinical diagnostics. For instance, cell counting products are extensively used in cancer research to determine intra-tumor heterogeneity, for assessment of cancer progression, and others.

Cell counting techniques are used for the identification and determination of primary tumor, circulating tumor, and metastatic tumor—important functions for disease monitoring. They have become part of standard diagnostic procedures in healthcare facilities, such as clinic and hospital settings. For instance, the full blood cell count is often conducted to determine the concentration of RBCs, WBCs, platelets, and plasma in patients for the identification of certain viruses, bacteria, and pathogens as well as for determining immune response among patients.

The Hospitals and Diagnostic Laboratories Segment to Dominate the Market

Based on end-users, the hospitals and diagnostic laboratories segment is expected to record the fastest CAGR during the forecast period. The market dominance can be attributed to the considerable number of patients visiting these facilities with different health conditions.

A significant amount of cell counting procedures, such as blood cell count, plasma count, and others, are employed regularly for diagnostic purposes. Thus, extensive employment of cell counting techniques is anticipated to drive segmental market growth. Many regulatory bodies have mandated the cell counting procedures for some standard diagnostics that lead to higher adoption. These ultimately give rise to significant revenue generation and faster growth among the segment.

Recent Developments

• In 2019, the U.S. based giant, Agilent Technologies acquired BioTek Instruments, Inc. strengthening its position in the market
• In March 2017, Beckman Coulter, the U.S. based subsidiary of Danaher corporations, launched an upgraded version of CytoFLEX LX using the CytoFLEX flow cytometer technology